ID   PER-485
AC   CVCL_W984
AS   CVCL_IY97
SY   PER-485A
DR   Wikidata; Q54947199
RX   PubMed=12883040;
RX   PubMed=17117183;
RX   PubMed=27443263;
RX   PubMed=33937032;
CC   Doubling time: 53 hours (PubMed=17117183); 48 hours (PubMed=27443263).
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Miscellaneous: Sampling site from personal communication of Kotecha R.S.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): PubMed=17117183; PubMed=27443263; PubMed=33937032
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 8,12
ST   D16S539: 11
ST   D18S51: 12,16
ST   D19S433: 14,16.2
ST   D21S11: 30.2,31.2
ST   D2S1338: 24,25
ST   D3S1358: 16,18
ST   D5S818: 12
ST   D7S820: 10,11
ST   D8S1179: 13,15
ST   FGA: 20,24
ST   TH01: 6,9
ST   TPOX: 9
ST   vWA: 15,16
DI   NCIt; C122617; Infant acute lymphoblastic leukemia with MLL rearrangement
DI   ORDO; Orphanet_513; Acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_A8JU ! PER-494
SX   Female
AG   1Y
CA   Cancer cell line
DT   Created: 17-07-14; Last updated: 29-06-23; Version: 11
//
RX   PubMed=12883040;
RA   Kees U.R., Ford J., Watson M., Murch A.R., Ringner M., Walker R.L.,
RA   Meltzer P.S.;
RT   "Gene expression profiles in a panel of childhood leukemia cell lines
RT   mirror critical features of the disease.";
RL   Mol. Cancer Ther. 2:671-677(2003).
//
RX   PubMed=17117183; DOI=10.1038/sj.bjc.6603447;
RA   Beesley A.H., Palmer M.-L., Ford J., Weller R.E., Cummings A.J.,
RA   Freitas J.R., Firth M.J., Perera K.U., de Klerk N.H., Kees U.R.;
RT   "Authenticity and drug resistance in a panel of acute lymphoblastic
RT   leukaemia cell lines.";
RL   Br. J. Cancer 95:1537-1544(2006).
//
RX   PubMed=27443263; DOI=10.1038/leu.2016.165;
RA   Cruickshank M.N., Ford J., Cheung L.C., Heng J., Singh S., Wells J.,
RA   Failes T.W., Arndt G.M., Smithers N., Prinjha R.K., Anderson D.,
RA   Carter K.W., Gout A.M., Lassmann T., O'Reilly J., Cole C.H.,
RA   Kotecha R.S., Kees U.R.;
RT   "Systematic chemical and molecular profiling of MLL-rearranged infant
RT   acute lymphoblastic leukemia reveals efficacy of romidepsin.";
RL   Leukemia 31:40-50(2017).
//
RX   PubMed=33937032; DOI=10.3389/fonc.2021.631594;
RA   Cheung L.C., de Kraa R., Oommen J., Chua G.-A., Singh S., Hughes A.M.,
RA   Ferrari E., Ford J., Chiu S.K., Stam R.W., Kees U.R., Malinge S.,
RA   Kotecha R.S.;
RT   "Preclinical evaluation of carfilzomib for infant KMT2A-rearranged
RT   acute lymphoblastic leukemia.";
RL   Front. Oncol. 11:631594.1-631594.13(2021).
//